Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good post Nanomat...however, I don't think the two acquisitions and Bond can be put solely at the feet of AS...he would have had to run it by the Board and they obviously sanctioned it. It is what it is and we are where we are and we should all now move on.
As mentioned before Novartis may be one to watch.
They have an Investment arm and here are some interesting comments from their site:
'Since 1996, the Novartis Venture Fund has been growing and developing innovative life science companies and products across North America and Europe'
'We work with life science innovators across the healthcare spectrum'
'We actively seek out opportunities that demonstrate exceptional potential. '
'We specialize in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies. However, we remain open to exploring later-stage opportunities as well. We allocate up to USD 25 million for each company we engage with, allowing us to provide substantial support across various growth phases.'
'Whether your company is at seed stage or in later-stage development, we prefer to play an active role by taking a seat on the board.'
'Our fund invests in a wide array of companies working in biotechnology and biopharmaceuticals at all stages of growth and development.'
Now this is the most interesting coomment they make...
'While we do work with innovative life science companies and teams developing novel therapeutics and platforms in the biotechnology and biopharma space, we do not invest in medtech or diagnostics.'
Now all the above would fit the bill re the European Speciality Healthcare Fund...plus the last comment might explain why DX has been given a back seat on the Avacta website...until such time ????!!!!
And one thing we also know is that CC was Clinical Program Team Lead at Novartis.
Now look at some of their successful exits...
https://www.nvfund.com/exits-successes/mergers-acquisitions
Just a few points from my perspective :-
1 Although I hear the words about 'planned succession' it is pretty obvious to me that AS has hardly gone with a fond farewell from his side. And we do not know if/if not there may be any currently unknown issues yet to be raised from either side regarding events since the purchase of Launch in October 2022 and AS's departure.
2 Christina only officially takes over today - 1 May - as per the RNS with AS stepping down yesterday. She may not be able to currently address past issues for all kinds of reasons - including legal advice not to do so. It is therefore unfair in my view to make any kind of judgment until we hear from her again - especially about the future strategy with timelines for the Therapeutics side.
3 Christina is a smart cookie and if anyone here thinks that she doesn't understand the issues then 'watch this space'. She said 'everything is on the table' not once but twice in the presentation - and she will consider all things presented to her. As CEO she does not have to be an expert in all operational areas - only to have the nous and open mindedness to listen to advice - something I reckon AS clearly did not seek or take.
4 I very much doubt that she would have taken up the post if - as some here mischievously imply - she didn't know the potential having worked on the inside for the past two years. In addition, she has spoken to many people in the oncology sector and not just at AACR and is now in pole position as our CEO to move things forward.
5 I was very critical in the past about AS as CEO and was proved right about his disastrous Dx purchases - especially as I knew from my observations of EKF Diagnostics that AS was buying Coris and Launch in a falling market. Just check out the downward spiral of EKF's SP since end of 2021. So I personally cannot fathom why AS made those purchases at this particular time and with a Convertible Bond or 'Lead Weight' to the SP. As I said in previous posts - 'They saw him coming' in London parlance and he was well and truly shafted in my opinion - but at our expense! And the overall Dx business is still loss making - surprise surprise -and projections of EBITDA positive in the second half is just 'bovine manure' as it is still a loss and what 2025 will bring is anyone's guess. So now that we all know the damage that AS has done - and I agree that the CFO's position is 100% untenable as well - which is why he had a very short slot yesterday and then was not referred to again like a very bad smell.
6 So now that the 'monkey' so to speak has finally been removed and replaced with a 'kosher' (also London parlance - nothing to do with religion) 'organ grinder' let's do the right thing and as John Lennon might have put it - 'Give Christina a Chance'. As I say - today is just Day #1.
"As for the share price, it is already severely depressed and the rsi is still right down, and one thing that is highly likely, the lower this goes, the more fingers will be hovering over that buy button..."
And there is your answer.... Its not about fundamentals ....at least not yet...
I read somewhere Avacta wanted the two new companies to maintain their own identity..hence they have maintained their own websites and maybe the reason for DX not being full frontal on the updated Avacta website site which is so obviously now all about TX. I can understand the logic initially but now with the change of CEO I think it is time to go whole hog and redefine the DX side of the business as a seperate stramlined business. Perhaps it's already in the plan and will be one of the next steps.
Let's see what they do to bolster the board over the coming weeks. The replacement of CEO is a positive in the sense that the new CEO will now be acutely aware that this needs to be treated as a commercial venture, or they face the block.
As for the share price, it is already severely depressed and the rsi is still right down, and one thing that is highly likely, the lower this goes, the more fingers will be hovering over that buy button...
Forgot to say, that offer applies to existing HL clients.
I just sold a single share I had in Yu energy. Shame that I'd sold the rest of them when I did. I kept one as a bookmark to come back to one day. They went up 1200% after I sold.
Hallo Sheppy, for anyone who isn’t aware of Sheppy, this resident board spammer has been posting exclusively on the Avacta board since the 18th May 2018. All posts negative despite trying to convince everyone he is invested in the share....Oh and he's also purporting to be very wealthy. Anyone want to see what the loud mouth trolls first post was on Avacta?
"All you so called investors are deluded with this share. It has done absolutely nothing but disappoint. You are all waiting for the deluded woooosh that is simply not going to happen. The only way this share goes is downwards. some people on here are talking about this being �4 a share �. more like 4p. There is no interest in it because its a no hoper...get real for god sake!"
The price on that date was 17.5p. If you'd bought at that price you could've sold at a 10x return.
Gje, maybe. Could well be.
The other side of that coin is that no one wanted to buy on the news either and the price had to come off by 5-10% to attract buyers, so where are the new buyers to come from?
Only on better news, I guess, right now the risk reward would seem to favour a wait and see approach.
I know almost on one here cares but if it went to 40p just to get to 80p its a bagger.. To get to 160p it would have to 4 bags.
That, as a return (whatever system used), would be fantastic and not run of the mill. My point is the price of entry is absolutely critical.
No one buys if they think it likely the SP will fall further.
CC did nothing to inspire me (as a for instance) to rush out and buy the stock on what was presented or what was sid or what was forecasted.
In fact the replacement of a CEO is a negative, and the cash burn feels like its bordering on out of control. (I don't mean running out of control, but can't be controlled internally and is subject to events.
Its about risk management.
(If there is anyone here who thinks they have lost so much its not worth selling now, then thats an example of poor risk management.)
One thing is apparent to me, there are many here who seem to have no appreciation on this aspect of investing and actually, all joking aside, that really is a trait of a gambler.
Hurst...how do you know she will be in NY at time of ASCO24 in Chicago? Do you know for a fact she will continue to be based in NY as CEO...or is it because her Linkedin page hasn't been changed.
'Christina Coughlin
Philadelphia, Pennsylvania, United States'
One to watch is:
Janet Munro
Head Program Innovation, Global Drug Development at Novartis
Switzerland
Already made comment about Avacta's trial data...
Watching we should listen to you . I’m in at 68 p 🎉 how great am I? And furthermore I’m rather pleased with myself
Has anyone else seen this on HL?
'BETTER VALUE TRADING
What would you do with £100 of free trades?
Join the UK’s no 1 stockbroker for individual investors and you can get £100 back on online trading charges until 21 June. Terms and other costs apply.'
Anyway, I wrote asking for clarification as there isn't much detail and I've received this reply:
'Dear Mr D-Geeman
Thank you for the message.
There is nothing that you need to do, you just have to buy or sell shares and £100 worth of the dealing charges would be refunded to you.
I hope this has been of assistance. If you have any further questions, please reply by secure message from your HL account or send us an email. Please note that attachments we send will only be available to view on our website and not on the HL App.
Kind regards
D H
Hargreaves Lansdown '
So something to bear in mind in these volatile times.
They need Simon Bennett off the wage bill. The guy is stealing a living, a third of the year doing sweet fa. Given a free pass until H2 this year before Avacta announce a pipeline, so no deals before then either. Get the company sold and put me out of my misery.
Winne charts are hocus pocus you can make numbers read anything. So bugger off 🤡
Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/
Could happen in a trice….
Volume is drying up, so I'd say it was just a minor sell off from traders such as yourself wyndrum following the presentation yesterday, where you clearly made the decision there's not a short term plate of chips to be had.
Will be company defining. Just like AACR was.
When Winne has writers cramp. He Pops back on here. As sheppy . Hilarious 🤣
No problem to me in the slightest
Sheppy you are getting one hell of a bashing on this BB today. 🤣🤣🤣
Jesus won’t save Avacta either
Jesus we are currently in commercial discussions and have strengthened our negotiating position, you either believe the deals will be forthcoming or you don’t, all this about oh you need xyz approvals first on previous drugs etc is hypothetical BS. The data on the platform is currently exceptional it sells itself, it won’t be BP dictating the term’s imo, Avacta will be in full control trying to maximise terms to benefit the company hence strengthening of Negotiation position. Why do you think they are so relaxed and excited about everything. Unfortunately MM games and a short position have caused mass panic here 19-20% Dilution caused an 80% drop didn’t think Avacta expected that tbh and totally not justified based on the fact nothing has materially changed since November (Al paid with his job), if Avacta were really concerned about share price they could release the early case studies to main stream media, the fact they haven’t bothered, suggest’s they know everything will take care of itself in time. These doom merchants crack me up 😆.
keep in mind that the fudsters are only interested in shares that have potential, that's why they hang around this one like flies around ****. if there was no potential they'd clear off to find a better pile of dung.
I wonder whether Phase 1 will be used to produce Avacta's first peer reviewed paper. Sometime this year, next year, somewhen.
Conference in Chicago, CC in NY